<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570089</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 10465</org_study_id>
    <nct_id>NCT00570089</nct_id>
  </id_info>
  <brief_title>Microvascular Coronary Disease In Women: Impact Of Ranolazine</brief_title>
  <official_title>Microvascular Coronary Disease In Women: Impact Of Ranolazine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CV Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To evaluate the impact of ranolazine extended-release tablets in women with
           subendocardial ischemia due to microvascular endothelial dysfunction on myocardial
           ischemia (Cardiac Magnetic Resonance (CMR) extent, severity.

        2. To evaluate the impact of ranolazine extended-release tablets in women with
           subendocardial ischemia due to microvascular endothelial dysfunction on the outcomes of
           angina (Seattle Angina Questionnaire (SAQ), WISE angina frequency, Duke Activity Status
           Inventory(DASI) and SF-36).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Interested women will be considered for the study if they meet inclusion and exclusion
      criteria including review of baseline CMR, ECG and blood work (liver and kidney function).
      The baseline CMR must be completed within 12 months previous to enrollment.

      Eligible women with angina and CMR subendocardial perfusion abnormalities, defined as CMR
      qualitative perfusion abnormalities of greater than or equal to 10% reported as abnormal
      following blind review per protocol, will be consented and enrolled. The women will complete
      baseline demographic and health history questionnaires, including the SAQ, Women's Ischemic
      Syndrome Evaluation (WISE) angina frequency, DASI and SF-36.

      This study is a double-blind, placebo controlled, cross-over design in which treatment order
      to ranolazine and placebo will be randomly assigned. Note: The participant's usual medication
      regimen will be continued throughout study participation. Following enrollment into the
      study, participants will be randomized to treatment #1 (either placebo or ranolazine).
      Ranolazine will be dosed as 500 mg orally twice daily for 2 weeks and, assuming tolerance,
      followed by 1000 mg orally twice daily for an additional 2 weeks. If the participant is
      unable to increase dose secondary to side effects, she will remain on 500 mg twice daily for
      the second 2 week interval. The first end of treatment CMR (CMR 1) will be scheduled at the
      end of the 4th week of treatment, approximately 4 hours after the morning dose of study drug.
      At this visit (Vis 2), concurrent medications, symptoms, and adverse events will be reviewed.
      Clinical measurements will be taken (weight, BP, waist and hip circumference) and
      questionnaires will be completed (SAQ, WISE angina frequency, DASI and SF-36).

      After the first course of study treatment, the patient will undergo a two week wash-out with
      no study drug while continuing usual medication regimen. Following the washout period, study
      participants will start the second cycle of study drug treatment (i.e., the other study drug
      not received in treatment 1). At visit 3, participants will undergo baseline 2 measurements
      which include concurrent medication and symptom assessment, clinical measurements (weight,
      BP, waist and hip circumference) and will complete baseline 2 questionnaires (SAQ, WISE
      angina frequency, DASI and SF-36). Study drug treatment #2 will follow the same escalation of
      study drug dose as described above for treatment 1. The final study CMR (CMR 2) will be
      scheduled at the end of the 4th week of treatment 2, approximately 4 hours after the morning
      dose of study drug. At this visit (Vis 4), concurrent medications, symptoms, and adverse
      events will be reviewed. Clinical measurements will be taken (weight, blood pressure, waist
      and hip circumference) and questionnaires will be completed (SAQ, WISE angina frequency, DASI
      and SF-36). [See Table 1 for a listing of all study procedures by visit.] The two post study
      drug treatment CMRs will be performed at the same time of day, replicating temperature,
      fasting state, adenosine dosing and infusion, magnet settings and using the same over-reader.
      The dose of adenosine will be consistent for all study CMR tests: 140 mcg/kg over 5 minutes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Magnetic Resonance (CMRs)</measure>
    <time_frame>4 weeks and 10 weeks</time_frame>
    <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion defect in percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Seattle Angina Questionnaire (SAQ)</measure>
    <time_frame>4 weeks and 10 weeks</time_frame>
    <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Each final SAQ domain ranges from 0-100, where higher is a better outcome score. Subscales are not combined. Median, SD and range are calculated for each domain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Study Drug Ranexa, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received study drug Ranexa, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
After a washout period of 2 weeks, they then received Placebo tablet (matching Ranexa tablet).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Study Drug Ranexa(Ranolazine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received Placebo tablet (matching Ranexa tablet) for two weeks.
After washout period of 2 weeks, they then received Ranexa 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.</description>
    <arm_group_label>Study Drug Ranexa, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Study Drug Ranexa(Ranolazine)</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.</description>
    <arm_group_label>Study Drug Ranexa, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Study Drug Ranexa(Ranolazine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women with signs and symptoms of myocardial ischemia (chest pain, abnormal stress
             testing, abnormal noninvasive testing) in the absence of obstructive coronary artery
             disease (epicardial coronary stenosis &lt;50% luminal diameter stenosis).

          2. Women with ≥10% myocardial ischemia by CMR perfusion.

        Exclusion Criteria:

          1. Contraindications to withholding nitrates, beta-blockers, calcium channel agents,
             ACE/ARB agents for 48 hours prior to testing.

          2. Contraindications in CMR including AICD, pacemaker, untreatable claustrophobia or
             known angio-edema.

          3. Contraindications to ranolazine including hepatic insufficiency, prolonged QT, renal
             failure.

          4. Women taking drugs that inhibit CYP3A such as diltiazem, verapamil, ketoconazole,
             macrolides or HIV protease inhibitors.

          5. Women less than 18 years of age.

          6. Women on drugs that prolong the QT interval such as Class Ia or III antiarrhythmic
             agents, erythromycin, certain antipsychotics.

          7. Pregnancy or breast feeding.

          8. Life expectancy less than 6 months.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Noel Bairey-Merz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHSP</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Chaitman BR. Ranolazine for the treatment of chronic angina and potential use in other cardiovascular conditions. Circulation. 2006 May 23;113(20):2462-72. Review.</citation>
    <PMID>16717165</PMID>
  </reference>
  <reference>
    <citation>Buchthal SD, den Hollander JA, Merz CN, Rogers WJ, Pepine CJ, Reichek N, Sharaf BL, Reis S, Kelsey SF, Pohost GM. Abnormal myocardial phosphorus-31 nuclear magnetic resonance spectroscopy in women with chest pain but normal coronary angiograms. N Engl J Med. 2000 Mar 23;342(12):829-35.</citation>
    <PMID>10727587</PMID>
  </reference>
  <reference>
    <citation>Doyle M, Fuisz A, Kortright E, Biederman RW, Walsh EG, Martin ET, Tauxe L, Rogers WJ, Merz CN, Pepine C, Sharaf B, Pohost GM. The impact of myocardial flow reserve on the detection of coronary artery disease by perfusion imaging methods: an NHLBI WISE study. J Cardiovasc Magn Reson. 2003 Jul;5(3):475-85.</citation>
    <PMID>12882078</PMID>
  </reference>
  <reference>
    <citation>Hundley WG, Hamilton CA, Thomas MS, Herrington DM, Salido TB, Kitzman DW, Little WC, Link KM. Utility of fast cine magnetic resonance imaging and display for the detection of myocardial ischemia in patients not well suited for second harmonic stress echocardiography. Circulation. 1999 Oct 19;100(16):1697-702.</citation>
    <PMID>10525488</PMID>
  </reference>
  <reference>
    <citation>Hundley WG, Hillis LD, Hamilton CA, Applegate RJ, Herrington DM, Clarke GD, Braden GA, Thomas MS, Lange RA, Peshock RM, Link KM. Assessment of coronary arterial restenosis with phase-contrast magnetic resonance imaging measurements of coronary flow reserve. Circulation. 2000 May 23;101(20):2375-81.</citation>
    <PMID>10821813</PMID>
  </reference>
  <reference>
    <citation>Hundley WG, Morgan TM, Neagle CM, Hamilton CA, Rerkpattanapipat P, Link KM. Magnetic resonance imaging determination of cardiac prognosis. Circulation. 2002 Oct 29;106(18):2328-33.</citation>
    <PMID>12403662</PMID>
  </reference>
  <reference>
    <citation>Johnson BD, Shaw LJ, Buchthal SD, Bairey Merz CN, Kim HW, Scott KN, Doyle M, Olson MB, Pepine CJ, den Hollander J, Sharaf B, Rogers WJ, Mankad S, Forder JR, Kelsey SF, Pohost GM; National Institutes of Health-National Heart, Lung, and Blood Institute. Prognosis in women with myocardial ischemia in the absence of obstructive coronary disease: results from the National Institutes of Health-National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004 Jun 22;109(24):2993-9. Epub 2004 Jun 14.</citation>
    <PMID>15197152</PMID>
  </reference>
  <reference>
    <citation>Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, Klocke FJ, Bonow RO, Judd RM. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000 Nov 16;343(20):1445-53.</citation>
    <PMID>11078769</PMID>
  </reference>
  <reference>
    <citation>Kim WY, Danias PG, Stuber M, Flamm SD, Plein S, Nagel E, Langerak SE, Weber OM, Pedersen EM, Schmidt M, Botnar RM, Manning WJ. Coronary magnetic resonance angiography for the detection of coronary stenoses. N Engl J Med. 2001 Dec 27;345(26):1863-9.</citation>
    <PMID>11756576</PMID>
  </reference>
  <reference>
    <citation>Nagel E, Lehmkuhl HB, Bocksch W, Klein C, Vogel U, Frantz E, Ellmer A, Dreysse S, Fleck E. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: comparison with dobutamine stress echocardiography. Circulation. 1999 Feb 16;99(6):763-70.</citation>
    <PMID>9989961</PMID>
  </reference>
  <reference>
    <citation>Nagel E, Klein C, Paetsch I, Hettwer S, Schnackenburg B, Wegscheider K, Fleck E. Magnetic resonance perfusion measurements for the noninvasive detection of coronary artery disease. Circulation. 2003 Jul 29;108(4):432-7. Epub 2003 Jul 14.</citation>
    <PMID>12860910</PMID>
  </reference>
  <reference>
    <citation>Panting JR, Gatehouse PD, Yang GZ, Grothues F, Firmin DN, Collins P, Pennell DJ. Abnormal subendocardial perfusion in cardiac syndrome X detected by cardiovascular magnetic resonance imaging. N Engl J Med. 2002 Jun 20;346(25):1948-53.</citation>
    <PMID>12075055</PMID>
  </reference>
  <reference>
    <citation>Schwitter J, DeMarco T, Kneifel S, von Schulthess GK, Jörg MC, Arheden H, Rühm S, Stumpe K, Buck A, Parmley WW, Lüscher TF, Higgins CB. Magnetic resonance-based assessment of global coronary flow and flow reserve and its relation to left ventricular functional parameters: a comparison with positron emission tomography. Circulation. 2000 Jun 13;101(23):2696-702.</citation>
    <PMID>10851206</PMID>
  </reference>
  <reference>
    <citation>Wahl A, Paetsch I, Gollesch A, Roethemeyer S, Foell D, Gebker R, Langreck H, Klein C, Fleck E, Nagel E. Safety and feasibility of high-dose dobutamine-atropine stress cardiovascular magnetic resonance for diagnosis of myocardial ischaemia: experience in 1000 consecutive cases. Eur Heart J. 2004 Jul;25(14):1230-6.</citation>
    <PMID>15246641</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2007</study_first_submitted>
  <study_first_submitted_qc>December 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 10, 2007</study_first_posted>
  <results_first_submitted>July 19, 2011</results_first_submitted>
  <results_first_submitted_qc>October 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 3, 2015</results_first_posted>
  <last_update_submitted>September 21, 2017</last_update_submitted>
  <last_update_submitted_qc>September 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Noel Bairey Merz</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Ranolazine</keyword>
  <keyword>Myocardial ischemia</keyword>
  <keyword>Double blinded</keyword>
  <keyword>Placebo controlled</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>20 subjects were recruited at Cedars-Sinai Medical Center Cardiology outpatient clinic.</recruitment_details>
      <pre_assignment_details>This is a cross-over study. 20 subjects (10 in study drug arm and 10 in placebo arm) completed period 1. In period 2, the 10 subjects who were on study drug in period 1 were on placebo arm in period 2, and the 10 subjects who were on placebo arm in period 1 were on study drug arm in period 2. The 20 subjects had a 2-week wash out in between.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Study Drug Ranexa Then Placebo</title>
          <description>20 subjects (10 in study drug arm and 10 in placebo arm) completed period 1. In period 2, the 10 subjects who were on study drug in period 1 were on placebo arm in period 2, and the 10 subjects who were on placebo arm in period 1 were on study drug arm in period 2. The 20 subjects had a 2-week wash out in between.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Then Study Drug Ranexa</title>
          <description>20 subjects (10 in study drug arm and 10 in placebo arm) completed period 1. In period 2, the 10 subjects who were on study drug in period 1 were on placebo arm in period 2, and the 10 subjects who were on placebo arm in period 1 were on study drug arm in period 2. The 20 subjects had a 2-week wash out in between.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Perod 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants who were randomized to receive either Study drug Ranexa or Placebo.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" lower_limit="46" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Magnetic Resonance (CMRs)</title>
        <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion defect in percentage.</description>
        <time_frame>4 weeks and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug Ranexa - CMRs (10 CMR 1 and 10 CMR 2)</title>
            <description>CMRs (CMR 1 and CMR 2) were performed to test the efficiency of the treatment of the study drug.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - CMRs (10 CMR 1 and 10 CMR 2)</title>
            <description>CMRs (CMR 1 and CMR 2) were performed to test the efficiency of the treatment of the study drug.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Magnetic Resonance (CMRs)</title>
          <description>Cardiac Magnetic Resonance (CMRs) (CMR 1 and CMR 2) end of the 4th week of treatment 1 and treatment 2 respectively, 4 hours after the morning dose of study drug was performed to measure myocardial perfusion defect in percentage.</description>
          <units>Percentage of ischemic myocardium</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" lower_limit="8.0" upper_limit="19.3"/>
                    <measurement group_id="O2" value="16.0" lower_limit="8.6" upper_limit="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seattle Angina Questionnaire (SAQ)</title>
        <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Each final SAQ domain ranges from 0-100, where higher is a better outcome score. Subscales are not combined. Median, SD and range are calculated for each domain.</description>
        <time_frame>4 weeks and 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Drug</title>
            <description>Study drug Ranexa arm</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo arm</description>
          </group>
        </group_list>
        <measure>
          <title>Seattle Angina Questionnaire (SAQ)</title>
          <description>Questionnaires will be completed (SAQ - Seattle Angina Questionnaire) at the end of each treatment period.
The Seattle Angina Questionnaire (SAQ) is a self-administered, 19-item questionnaire, a cardiac disease-related quality-of-life measure. The SAQ is well validated and sensitive to clinical changes. It has five subscales: physical limitation, angina stability, angina frequency, treatment satisfaction, and disease perception. The possible range of scores for each of the five subscales is 0 to 100, with higher scores indicating better quality of life. A change of 10 points in any of the subscales is considered to be clinically important.
Each final SAQ domain ranges from 0-100, where higher is a better outcome score. Subscales are not combined. Median, SD and range are calculated for each domain.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Physical Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7" lower_limit="79.2" upper_limit="97.9"/>
                    <measurement group_id="O2" value="83.3" lower_limit="66.6" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina Stability</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="50" upper_limit="100"/>
                    <measurement group_id="O2" value="50" lower_limit="25" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Angina Frequency</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="50" upper_limit="100"/>
                    <measurement group_id="O2" value="75" lower_limit="60" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Satisfaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="75" upper_limit="100"/>
                    <measurement group_id="O2" value="93.8" lower_limit="75" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Quality of Life</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75" lower_limit="60.4" upper_limit="83.3"/>
                    <measurement group_id="O2" value="66.7" lower_limit="58.3" upper_limit="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>10 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Drug</title>
          <description>Study drug Ranexa arm</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo arm</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This was a pilot study.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>C. Noel Bairey Merz, MD</name_or_title>
      <organization>Cedars-Sinai Medical Center</organization>
      <phone>310-423-9680</phone>
      <email>merz@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

